Wogonin, a flavonoid derived from the plant Scutellaria baicalinase's, has emerged as a promising candidate for sepsis management due to its multifaceted pharmacological properties. A comprehensive search of databases, including Google Scholar, Scopus, Web of Science, PubMed, and Embase, was conducted up to November 2025 using relevant keywords. In-vivo studies were assessed using the SYRCLE risk of bias tool, and in-vitro studies were evaluated with the OHAT risk of bias tool. A total of 449 articles were initially sourced, ultimately, 24 publications included in this systematic review. Evidence from various in-vivo and in-vitro studies indicates that wogonin exerts protective effects against sepsis-induced organ damage by modulating critical signalling pathways such as NF-κB, MAPK, and Nrf2/HO-1. Despite these promising findings, further clinical trials are necessary to establish the safety and efficacy of wogonin in human subjects suffering from sepsis.
Farah et al. (Fri,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: